3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Surveys and Questionnaires
4
Nivolumab
3
pembrolizumab
2
cemiplimab
2
atezolizumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
trametinib
1
repotrectinib
1
pralsetinib
1
pazopanib
1
motexafin gadolinium
1
durvalumab
1
dabrafenib
1
avelumab
1
alectinib
1
Transurethral Resection of Prostate
1
Tomography, X-Ray Computed
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiosurgery
1
Quality of Life
1
Patient-Specific Modeling
1
Oncolytic Virotherapy
1
Ocoxin
1
Observation
1
Mass Screening
1
MLN 8237
1
Immune Checkpoint Inhibitors
1
Hyperspectral Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
alectinib
×
Head & Neck
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts